Case study

Reference: IMD-3-2137

Order this case study

The new Merck: Beating the odds (B)

By Professor Benoit F. Leleux and Anne-Catrin Glemser

DARMSTADT, SEPTEMBER 2009. Jon Baumhauer, Chairman of the Merck Family Council and an influential member of the E. Merck KG Executive Board, could not hide a smile as he recollected the confidential first meeting together with members of the Merck KGaA Executive Board with Ernesto Bertarelli and his Serono advisor on 19 September 2006:

“When Serono got back to us after months of trying to sell itself to every big pharma in the world, they were of course anxious to get a deal done quickly. But not that quickly… When they asked how long it would take Merck to get back to them, I told them, ‘Negotiations can start immediately.’ That took the air right out of them. They clearly underestimated the family cohesion and their ability to rally behind the deal. We had discussed this internally for months, and the family was 100% involved. I did not need to go back to them: They had given their formal approval. That very much sealed the deal. This is what family can do in business…”.

The Serono acquisition proved a defining moment for both the family and the company, a truly transformational merger. Merck became one of the world’s leading biotech companies and the seventh largest pharmaceutical company in Europe. It gave the combined group the R&D firepower and critical mass to play in the same league as the “big pharma” players, Amgen and Roche. It was: “…not a scale or size merger, but a knowledge and capability merger. Our two companies are complementary and together create one that, in the mid-size arena, has world-class knowledge in biotech and small molecules.”

But challenges remained. Had the firm finally reached an efficient scale? Would impending profound changes to health policies wreak havoc with current profit drivers? Would it be possible to maintain the coherence and integrity of the family with the company’s exploding size? Would family ownership continue to decline? 

Learning Objective

Managing a family business for sustainability; sophisticated family and business governance structures; managing growth; technology innovation; maintaining the entrepreneurial spirit; multi-generation family business; critical size and growth issues in the pharma business; managing incentive systems for executives; managing a transformational merger.

KeywordsAcquisition, Critical Mass, Due Process, Family, Family Business, General Management, Going Public, Governance, Growth Strategy, Meritocracy, Pharmaceuticals, Succession, Transformational Merger
SettingsGermany
Serono
2006-2009
TypeField Research
Copyright©2009
LanguageEnglish
Related materialTeaching notes, video
Order this case study

Reference: IMD-3-2137

IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Fax +44 (0)1234 751125
Email info@thecasecentre.org

The Case Centre Babson College

Babson Park Wellesley MA 02457, USA
Tel +1 781 239 5884
Fax +1 781 239 5885
Email info.usa@thecasecentre.org

Harvard Business School Publishing

60 Harvard Way Boston, MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email custserv@hbsp.harvard.edu

Case Center Japan

2nd Floor, Toranomon Jitsugyokaikan,
1-1-20 Toranomon, Minato-ku,
Tokyo 105-0001 Japan
Tel +81 3 3503 6621
Fax +81 3 3501 0550
Email info@casecenter.jp

Copyright information

IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information, please contact our Information Center.

Do you need more information?
Contact us for additional information or republishing

Case study

Reference: IMD-3-2137

Order this case study

Other case study in this series

The Mercks of Darmstadt: What family can do (A)


Looking for something specific?

Keep reading